---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-034667"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2024-03-21T23:59:59+00:00"
generated_at: "2026-06-04T09:58:27.627109+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Dianthus reports FY2023 net loss $43.6M, cash $389M; Phase 2 gMG trial initiated

## Summary
- FY2023 net loss $43.6M ($8.45/share), R&D $32.8M, G&A $18.2M.
- Pro forma cash $389M (including $216M net from Jan 2024 PIPE); runway to 2H 2027.
- Phase 2 MaGic gMG trial initiated Feb 2024; top-line data expected 2H 2025.
- Phase 2 trials planned: MMN (Q2 2024) and CIDP (2H 2024).
- Jeffrey Stavenhagen appointed CSO in Nov 2023.

## SEC filing metadata
- accession: 0000950170-24-034667
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2024-03-21T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017024034667/0000950170-24-034667-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017024034667/dnth-20240321.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-034667
- JSON: https://secwatch.observer/filing/0000950170-24-034667.json
- Plain text: https://secwatch.observer/filing/0000950170-24-034667.txt

## Key facts
- Earnings Releases
  Dianthus Therapeutics, Inc. /DE/ reported the year ended December 31, 2023 results: net income $43.6 million, EPS $8.45 net loss per share (basic and diluted).
  - Period: the year ended December 31, 2023
  - Net income: $43.6 million
  - EPS: $8.45 net loss per share (basic and diluted)
  - Result: reported results
  source text: Net loss for the year ended December 31, 2023 was $43.6 million or $8.45 net loss per share (basic and diluted)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000095017024034667/0000950170-24-034667-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.